34 European civil society organizations call on EU political leadership to urgently address communicable diseases such as HIV/AIDS, tuberculosis and hepatitis C epidemics in the European Union and neighbouring countries.

As countries improve and scale up their diagnostic services, increasing number of patients with multidrug-resistant TB and extensively drug-resistant TB are identified. Bedaquiline and delamanid offer a real opportunity to improve the outcomes of these patients. After so many decades without new TB drugs the development of these two new medicines is an historic opportunity to gain ground in the fight against TB.

TB is the leading cause of death for people living with HIV and killed 1.5 million people globally in 2014 alone. TB treatment has become more complex, particularly with the emergence of multidrug-resistant strains of TB. The Medicines Patent Pool, the world’s only voluntary licensing mechanism in public health, will now work to ensure access to new treatments for drug-resistant and drug-susceptible TB.

This is the first language guide for partners and stakeholders working in TB and supports the Global Plan to End TB 2016-2020 paradigm shift ‘changing the mindset, language, and dialogue on TB’.

The Bali Declaration unites more than 100 global health officials and experts behind a global campaign to fight the twin scourge of TB and diabetes. New data show 1 in 4 people with TB also have diabetes in hot spots in India.

Equity Pharmaceuticals is the new supplier of the drug.

The report provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care, control and research at global, regional and country levels. With 1.5 million people killed by TB in 2014, the disease ranks alongside HIV as a leading killer worldwide. 

Launch of the Lancet TB Series on 'How to Eliminate TB': Unless there is a major shift in the way the world fights tuberculosis - from a reliance on biomedical solutions to an approach that combines biomedical interventions with social actions - the epidemic and drug resistance will worsen.

The conference will take place 16-17 July, 2016 in Durban, South Africa, immediately preceding the 21st International AIDS Conference (AIDS 2016). The meeting is a unique partnership between HIV and TB scientists and advocates, convened to draw attention around the need for greater urgency and innovation to combat both epidemics.

The cost of newer drugs for the treatment of multidrug-resistant tuberculosis could be cut by up to 95% if generic production of patented products could be achieved in the same way as for antiretroviral drugs.